Jia Hu

Dr. Jia Hu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Medicine
Verified
Journal Article
Open access
ALan luo
an luo
NQNan Mm Qiao
Nan Mm Qiao
JHJia Hu
Jia Hu
HXHenglang Xu
Henglang Xu
MXMingjun Mm Xie
Mingjun Mm Xie
JHJia Hu
Jia Hu
Pancreatic adenocarcinoma is the most common malignant tumor of the digestive system and is called the “king of cancer” because it has been labeled with high malignancy, rapid progression, poor survival, and poor prognosis. Previously, it was reported that the basic leucine zipper and W2 domains 1 (BZW1) is involved in the progression of many tumors. However, its research in digestive system tumors such as pancreatic cancer is rarely studied. To explore potential biomarkers related to survival and prognosis of pancreatic cancer and provide a new targeted therapy for it. We first analyzed the mRNA and protein expression of BZW1 in pancreatic cancer. We then explored the correlation of BZW1 with survival prognosis and immune infiltration in pancreatic cancer patients. Finally, we explored BZW1-related gene enrichment analysis, including protein-protein interaction networks, gene ontology functional enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The mRNA and protein expression of the BZW1 gene in pancreatic cancer tissues were higher than those in adjacent normal tissues, and pancreatic cancer patients with high BZW1 expression had a poor prognosis. In addition, the expression of BZW1 was positively or negatively correlated with different immune cells of pancreatic cancer, such as CD4 + T lymphocytes, CD8 + T lymphocytes, B cells, macrophages, neutrophils, etc. Correlation enrichment analysis showed that we obtained 50 available experimentally determined BZW1-binding proteins and 100 targeted genes related to BZW1, and the intersection genes were eukaryotic translation termination factor 1 and Guanine nucleotide binding protein, alpha inhibiting activity polypeptide 3. Moreover, there was a positive correlation between BZW1 and eukaryotic translation termination factor 1 and Guanine nucleotide binding protein, alpha inhibiting activity polypeptide 3 genes in pancreatic cancer. Gene ontology enrichment analysis showed BZW1 was mainly related to biological processes such as “mRNA processing,” “RNA splicing,” “regulation of translational initiation,” and “activation of innate immune response.” The results of Kyoto Encyclopedia of Genes and Genomes pathway analysis further indicated that BZW1 may be involved in pancreatic carcinogenesis through the “spliceosome” and “ribosome.” The BZW1 gene may be a potential immunotherapy target and a promising prognostic marker for pancreatic cancer.

26 November 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CZChao Zhong
Chao Zhong
ZCZhaorui Cheng
Zhaorui Cheng
YSYuansen Shu
Yuansen Shu
XYXiaojuan Yang
Xiaojuan Yang
JHJia Hu
Jia Hu
YLYun Liu
Yun Liu
Background Colorectal cancer (CRC) stands as the most common gastrointestinal malignancy, with the Follistatin-like 1 (FSTL1) gene associated with unfavorable outcomes in diverse cancer forms. Nonetheless, the precise mechanisms through which FSTL1 influences CRC pathogenesis and its associated multi-omics characteristics remain unclear. Methods This study leveraged RNA sequencing and single-cell RNA sequencing (scRNAseq) data from the Gene Expression Omnibus (GEO) database to scrutinize the expression profile, prognostic significance, and clinicopathological relevance of FSTL1 in colorectal cancer. Gene set enrichment analysis (GSEA) and protein-protein interaction (PPI) network analysis were conducted to delve into the potential biological functions of FSTL1 in colorectal cancer and its associated pathways. The ESTIM algorithm and Tumor Immune Estimation Resource (TIDE) database were utilized to investigate FSTL1 expression in immune cell infiltration and immune checkpoints. Mutation characteristics of FSTL1 were elucidated using the cBioPortal database. The pRRophetic package was employed to identify potential chemotherapeutic drugs targeting FSTL1. Expression levels of FSTL1 in colon cancer and adjacent normal tissues were evaluated using the Human Protein Atlas (HPA) database. Furthermore, single-cell sequencing technology and cell communication were employed to assess the immunogenomic features of FSTL1 in the tumor microenvironment. In vitro experiments were conducted to validate the efficacy of FSTL1. Results FSTL1 levels were markedly higher in colorectal cancer tissues compared to healthy tissues, correlating significantly with unfavorable patient outcomes. Elevated FSTL1 expression was closely linked to key biological processes including the PI3K pathway, cell adhesion, proliferation, migration, and extracellular matrix remodeling. Furthermore, FSTL1 expression exhibited strong associations with immune cell levels and the tumor immune microenvironment in colorectal cancer. Notably, FSTL1 mutations predominantly comprised missense mutations and displayed significant correlations with various immune checkpoints and low methylation levels. Axitinib emerged as a promising targeted therapeutic option for patients with high FSTL1 expression. Analysis from the HPA database confirmed elevated FSTL1 expression in colorectal tissues compared to adjacent normal tissues. Single-cell sequencing analysis identified stromal cells as the primary source of abundant FSTL1 expression, potentially influencing tumor microenvironment remodeling by myeloid and B cells via the APP-CD74 pathway. Downregulating FSTL1 expression in colon cancer cells suppresses the proliferation, motility, and invasiveness of SW480 and HCT116 colon cancer cells. Conclusion In summary, the findings of the study indicate that elevated FSTL1 expression could serve as a prognostic biomarker for unfavorable outcomes in colorectal cancer (CRC) diagnosis and may also identify potential targets for immunotherapy in CRC.

16 June 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YFYing Fei
Ying Fei
MGMing-Yi Gao
Ming-Yi Gao
NQNan Qiao
Nan Qiao
JHJia Hu
Jia Hu
LHLing He
Ling He
TLTing-Ting Liu
Ting-Ting Liu
Background: The effect of fecal microbiota transplantation (FMT) in treating irritable bowel syndrome (IBS) may be attributed to the modulation of CD8 + T cells. This study aims to identify FMT-mediated key genes to explore the underlying mechanism. Methods: Transcriptomic datasets GSE138297 (colonic biopsies from 8 IBS patients pre- and post-FMT) and GSE134649 (single-cell data from 3 healthy colon tissues) were obtained from GEO during December 2023–December 2024. Key genes were identified by intersecting differentially expressed genes (DEGs) and the most relevant co-expression module derived from weighted correlation network analysis. Functional enrichment, gene set enrichment analysis, immune infiltration profiling via TIMER 2.0, single-cell annotation using PanglaoDB and Seurat, and drug–gene interaction screening from DrugBank were conducted to decipher the regulatory mechanisms. Results: Ten key genes were identified through integration of DEGs and the MEgreen module. Functional analyses revealed significant involvement in the positive regulation of CD8 + T cells activation. Immune infiltration assessment demonstrated a marked increase in CD8 + T cells abundance post-FMT. Single-cell data indicated predominant expression of LILRB1, P2RY13, CLEC10A, and CLEC12A in dendritic cells, and LILRB1, PIPOX, and CLEC11A were annotated within CD8 + T cells clusters in healthy colonic tissue. Nine (database-derived and speculative) drugs targeting seven key genes were identified, most implicated in the management of IBS symptoms or immunomodulation. Conclusion: An association between key gene regulation and CD8 + T cell-related immunoregulation is correlated with the therapeutic effect of FMT in IBS.

22 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
ALan luo
an luo
HXHenglang Xu
Henglang Xu
MXMingjun Xie
Mingjun Xie
KHKe Hu
Ke Hu
YJYiping Jiang
Yiping Jiang
JHJia Hu
Jia Hu
Background Colorectal cancer (CRC) is the most common malignant tumor of the intestine, and its incidence and mortality rate are at the forefront. Early diagnosis and intervention of CRC is of great significance. however, there is a lack of precise diagnostic biomarkers. We aim to explore potential biomarkers for CRC and provide a new treatment idea for CRC. Methods We first identified differentially expressed genes (DEGs) in 26 colorectal tumor tissue samples and 26 matched non-tumor tissue samples in the GSE25070 dataset. We then performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEGs using the Database for Annotation Visualization and Integrated Discovery (DAVID). We further constructed protein-protein interaction (PPI) networks of DEGs using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database and screened 10 hub genes using Cytoscape software. GO and KEGG enrichment analysis of hub genes was done by the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt). Finally, we analyzed the expression levels and survival of hub genes using the Gene Expression Profiling Interactive Analysis (GEPIA) database. Results We obtained 756 DEGS (254 upregulated genes and 502 downregulated genes) from the GSE25070 dataset, and DEGs were mainly enriched in inflammatory response, neutrophil chemotaxis, and cytokine-cytokine receptor. Ten hub genes were identified, including five upregulated genes (VEGFA, IL1B, MMP9, CXCL8, and CCND1) and five downregulated genes (MAPK3, ADH1A, SLC26A3, ADH1C, and UGT1A8). Five upregulated genes were highly expressed in CRC patients, and IL1B and CXCL8 genes were significantly associated with overall survival in colorectal cancer patients, and high expression of IL1B and CXCL8 had a greater survival advantage. Conclusion IL1B and CXCL8 are potential biomarkers for CRC.